8-K: NanoViricides Secures $6M in Direct Offering and Private Placement

NanoViricides, Inc. has successfully closed a $6 million registered direct offering and concurrent private placement to fund working capital and general corporate purposes.

Summary

• NanoViricides, Inc. entered into a securities purchase agreement with a single healthcare institutional investor on November 10, 2025.
• The offering included a registered direct offering of 1,970,000 shares of common stock at $1.68 per share and pre-funded warrants to purchase up to 1,601,429 shares of common stock at $1.67999 per warrant.
• The pre-funded warrants have a nominal exercise price of $0.00001 per share and are immediately exercisable until fully exercised.
• A concurrent private placement involved the issuance of Series A Common Stock Purchase Warrants and Series B Common Stock Purchase Warrants, each for up to 3,571,429 shares of common stock.
• Series A Warrants are exercisable after 6 months at $1.75 per share and expire 2 years from issuance.
• Series B Warrants are exercisable after 6 months at $2.00 per share and expire 5.5 years from issuance, representing approximately a 20% premium to the common stock's closing price on November 10, 2025.
• The aggregate gross proceeds from the offering were approximately $6.0 million, before deducting placement agent fees and other offering expenses.
• The net proceeds are intended for working capital and general corporate purposes.
• A.G.P./Alliance Global Partners acted as the sole placement agent, receiving a 7.0% cash fee of the gross proceeds and reimbursement for up to $60,000 in legal fees and $15,000 in non-accountable expenses.
• The company's directors and executive officers entered into 90-day lock-up agreements for their common stock and equivalents.

Sentiment

Score: 5

Explanation: The capital raise provides essential funding for a clinical-stage biotech, which is a positive for continued operations. However, the significant potential dilution from the warrants and the ongoing need for capital in a high-risk industry temper the overall sentiment to neutral.

Positives

• Successfully raised approximately $6.0 million in gross proceeds, providing capital for working capital and general corporate purposes.
• Secured funding from a single healthcare institutional investor, indicating targeted investor interest.
• The Series B Warrants were priced at a 20% premium to the market closing price on November 10, 2025, suggesting confidence in future stock appreciation by the investor.
• The offering included pre-funded warrants with a nominal exercise price, allowing for immediate capital infusion with minimal future cash outlay from the holder for exercise.

Negatives

• The offering involves significant potential dilution from the issuance of 1,970,000 shares, 1,601,429 pre-funded warrants, and 7,142,858 common warrants (3,571,429 Series A and 3,571,429 Series B).
• The company incurred a 7.0% cash fee to the placement agent, plus up to $75,000 in expense reimbursements, reducing net proceeds.
• The company is restricted from issuing or announcing new equity for 90 days and from Variable Rate Transactions for 180 days, limiting immediate future financing flexibility.

Risks

• The path to typical drug development for any pharmaceutical product is extremely lengthy and requires substantial capital.
• There is no assurance that any of the company's pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development.
• Successful results against coronavirus in the lab do not guarantee successful clinical trials or a successful pharmaceutical product.
• The company's ability to project exact dates for filing Investigational New Drug (IND) applications is dependent on external collaborators and consultants.
• The company's stock is currently subject to delisting by the Trading Market, posing a risk to liquidity and investor confidence.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes. It is currently focused on advancing its lead drug candidate, NV-387, into Phase II human clinical trials for RSV, COVID, Long COVID, Influenza, other respiratory viral infections, and MPOX/Smallpox. The company is also developing NV-HHV-1 for Shingles and other drugs for various viral diseases, with plans to obtain additional licenses if initial research is successful.

Management Comments

• Anil Diwan is listed as President, Chairman, Chief Executive Officer.

Industry Context

This capital raise is typical for a clinical-stage biotechnology company like NanoViricides, which requires substantial funding to advance its drug candidates through lengthy and expensive development phases, including preclinical and human clinical trials. The issuance of warrants is a common incentive for institutional investors in such offerings, balancing immediate capital needs with future potential upside, albeit at the cost of potential dilution for existing shareholders. The focus on broad-spectrum antiviral drugs, including for COVID-19, RSV, and Influenza, aligns with ongoing global health priorities and the demand for effective treatments for infectious diseases.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Will experience immediate dilution from the issuance of common stock and potential future dilution upon exercise of the pre-funded and common warrants.
• Employees: Continued employment and R&D activities are supported by the new capital.
• Creditors: Improved liquidity from the capital raise may enhance the company's ability to meet its financial obligations.
• Investors (Purchasers): Gain exposure to the company's potential upside through common stock and warrants, with the pre-funded warrants offering immediate equity at a low exercise price.

Next Steps

• Use net proceeds for working capital and general corporate purposes.
• Advance lead drug candidate NV-387 into Phase II human clinical trials.
• Continue development of NV-HHV-1 for Shingles.
• Continue development of drugs against various other viral diseases.
• Obtain licenses for RSV, Poxviruses, and/or Enteroviruses if initial research is successful.
• Maintain listing or quotation of Common Stock on the Trading Market.
• Apply to list or quote all Shares and Warrant Shares on the Trading Market.
• File a registration statement on Form S-1 (Resale Registration Statement) within 30 calendar days for the resale of Warrant Shares.
• Cause the Resale Registration Statement to become effective within 60-90 days following filing and keep it effective until no Purchaser owns Warrants or Warrant Shares.

Key Dates

Recommendation

The capital raise provides crucial funding for NanoViricides, a clinical-stage biotech, enabling it to continue its drug development programs, particularly advancing NV-387 into Phase II trials. This is a necessary step for a company in this industry. However, the offering involves substantial potential dilution from the issuance of shares and multiple series of warrants, which could pressure the stock price. The inherent risks of drug development, including lengthy timelines and uncertain outcomes, remain significant. While the funding is positive for operational continuity, the speculative nature of the business and the dilutive terms suggest a 'hold' recommendation for seasoned investors, awaiting more definitive clinical trial results or clearer paths to commercialization before a stronger stance.

Keywords

NanoViricides, NNVC, Registered Direct Offering, Private Placement, Warrants, Pre-Funded Warrants, Series A Warrants, Series B Warrants, Capital Raise, Biotechnology, Antiviral Therapy, Drug Development, SEC Filing, Equity Offering, Dilution